Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q4 2017 call → NOThe question asks whether management lays out a timetable of specific conversions — identified pieces of business that are already secured or already in motion, each attached to an at-least-approximate time frame in which it starts contributing — so that the forward story reads as a schedule of things turning on, rather than as hopes about demand. Let me review the transcript for what management says about the next four or so quarters. Key forward-looking items mentioned: 1. NDA submission for lumateperone for schizophrenia by mid-2018 — this is a regulatory filing, not a "conversion" of secured business. It's contingent on FDA approval. 2. Pre-NDA meeting with FDA later this month (March 2018) — again regulatory. 3. Bipolar depression studies: Study 401 topline in second half 2018, Study 404 in 2019 — these are clinical trial results, not secured business. 4. Agitation in Alzheimer's disease: interim analysis in second half 2018 — clinical trial. 5. ITI-214 Phase 1/2 in Parkinson's: topline results second half 2018 — clinical trial. 6. ITI-214 heart failure study starting this month — clinical trial. 7. ITI-333 preclinical, entering clinic next year — not secured. 8. Commercial launch preparation for lumateperone — but no approval yet. The question asks about "conversions" — identified pieces of business that are already secured or already in motion, each attached to a time frame in which it starts contributing. This is about revenue-generating business, like contracts, orders, facilities opening, customers going live, etc. In this case, the company is a biotech with no approved products. All the forward items are clinical trials, regulatory filings, and development milestones. None of these are "secured business" — they are all contingent on clinical trial outcomes, FDA approvals, etc. There is no revenue yet. The company is pre-commercial. The forward story is about clinical development milestones, not about secured business converting to revenue. The items are all contingent on approvals, trial results, etc. There's no "already secured" business. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.